Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1248

Shown on this page

Current sort

Live official records

Conditions: Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Interventions: Non-Invasive Testing for PIFI; Diagnostic Test
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more

Conditions: Moderate to Severe Asthma
Interventions: Dupilumab, Benralizumab; Biological
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut

Conditions: Kidney Transplant Rejection
Interventions: Prospera; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more

Conditions: Coronary Artery Disease
Interventions: Microport Firehawk stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent); Device
Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 38 more

Conditions: ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions: MK-3795, Nivolumab, Cabozantinib, Bezlutifan; Drug
Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: Heart Diseases, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 74
States / cities: Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more

Conditions: Solid Tumor
Interventions: QN-302; Drug
Lead sponsor: Qualigen Theraputics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Grand Rapids, Michigan + 1 more

Conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck
Interventions: IO102-IO103, Pembrolizumab KEYTRUDA®; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Boston, Massachusetts • Richmond, Virginia

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions: Orbital Atherectomy, Balloon; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more

Conditions: Premature Birth, Antibiotics, Neurodevelopment
Interventions: Ampicillin, Gentamicin, Placebo; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions: Iomab-B, Conventional Care, HCT; Drug · Procedure
Lead sponsor: Actinium Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more

Conditions: Prostate Cancer
Interventions: docetaxel, LHRH agonist, surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 221
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

NICU Antibiotics and Outcomes (NANO) Follow-up Study

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

About this Yale institution page